The Institute for Neurosciences of Montpellier (INM) is the Joint Research Unit U1298 Inserm/University of Montpellier. It comprises 8 Inserm teams and a staff of 200 personnel working on sensory-motor deficits and neurodegeneration. INM aims to gather fundamental and translational research to study the development, synaptic plasticity and integration, and neurodegenerative processes leading to disorders of the central and sensory-motor systems.
Our fundamental research is the ground for the development of innovative therapeutic (cell and gene therapy) and diagnostic (genetics and proteomics) strategies for hereditary retinal and optic nerve blindness, corneal damages, auditory neuropathy (deafness and tinnitus), somatosensory diseases (touch and pain), sleep disorders, cognition disorders (autism, schizophrenia, environmental stress) and neurodegenerative diseases (amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease).
Research, from the molecular level to the integrated system, is conducted using cutting-edge technical platforms (functional analysis, stem cell and organoids, neurogenetics, proteomics, biostatistics and epidemiology, photonic and electronic imaging). Our translational research is based on strong interactions with clinical services (neurology, ophthalmology, ENT). We benefit from the support of patient associations and interact constructively with industry.
The INM is committed to the development of eco-responsible research
Using CRISPR/Cas9 to mediate allele-specfic knockout as a treatment for autosomal dominant retinitis pigmentosa
Identification of a new gene causing both dominant and recessive forms of the most frequent blinding inherited disorder: retinitis pigmentosa
Beginning: February 2022